Literature DB >> 21283041

Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma.

Chigusa Morizane1, Takuji Okusaka, Satoshi Morita, Katsuaki Tanaka, Hideki Ueno, Shunsuke Kondo, Masafumi Ikeda, Kohei Nakachi, Shuichi Mitsunaga.   

Abstract

OBJECTIVES: To identify prognostic factors in patients with metastatic pancreatic adenocarcinoma.
METHODS: The relationship between patient characteristics and outcome was examined by multivariate regression analyses of data from 409 consecutive patients with metastatic pancreatic adenocarcinoma who had been treated with a gemcitabine-containing regimen, and we stratified the patients into 3 risk groups according to the number of prognostic factors they had for a poor outcome. A validation data set obtained from 145 patients who had been treated with agents other than gemcitabine was analyzed. The prognostic index was applied the each of the patients.
RESULTS: The multivariate regression analyses revealed that the presence of pain, peritoneal dissemination, liver metastasis, and an elevated serum C-reactive protein value significantly contributed to a shorter survival time. The patients were stratified into 3 groups according to their number of risk factors, and their outcomes of the 3 groups were significantly different. When the prognostic index was applied to the validation data set, the respective outcomes of the 3 groups were found to be significantly differed from each other.
CONCLUSIONS: Pain, peritoneal dissemination, liver metastasis, and an elevated serum C-reactive protein value are important prognostic factors for patients with metastatic pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21283041     DOI: 10.1097/MPA.0b013e3182021376

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  16 in total

1.  Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.

Authors:  Naminatsu Takahara; Hiroyuki Isayama; Yousuke Nakai; Takashi Sasaki; Hironori Ishigami; Hiroharu Yamashita; Hironori Yamaguchi; Tsuyoshi Hamada; Rie Uchino; Suguru Mizuno; Koji Miyabayashi; Dai Mohri; Kazumichi Kawakubo; Hirofumi Kogure; Natsuyo Yamamoto; Naoki Sasahira; Kenji Hirano; Hideaki Ijichi; Keisuke Tateishi; Minoru Tada; Joji Kitayama; Toshiaki Watanabe; Kazuhiko Koike
Journal:  J Gastrointest Cancer       Date:  2014-09

2.  Conversion therapy for pancreatic cancer with peritoneal metastases using intravenous and intraperitoneal paclitaxel with S-1.

Authors:  Hiromitsu Kitayama; Yasushi Tsuji; Tomohiro Kondo; Junko Sugiyama; Michiaki Hirayama; Kazuyuki Yamamoto; You Kawarada; Yumiko Oyamada; Satoshi Hirano
Journal:  Mol Clin Oncol       Date:  2016-10-13

3.  Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.

Authors:  Tadayuki Kou; Masashi Kanai; Michio Yamamoto; Peng Xue; Yukiko Mori; Yasushi Kudo; Akira Kurita; Norimitsu Uza; Yuzo Kodama; Masanori Asada; Michiya Kawaguchi; Toshihiko Masui; Masaki Mizumoto; Shujiro Yazumi; Shigemi Matsumoto; Kyoichi Takaori; Satoshi Morita; Manabu Muto; Shinji Uemoto; Tsutomu Chiba
Journal:  Int J Clin Oncol       Date:  2015-06-28       Impact factor: 3.402

4.  Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.

Authors:  Naminatsu Takahara; Hiroyuki Isayama; Yousuke Nakai; Hironori Ishigami; Sohei Satoi; Suguru Mizuno; Hirofumi Kogure; Saburo Matsubara; Natsuyo Yamamoto; Hironori Yamaguchi; Minoru Tada; Joji Kitayama; Toshiaki Watanabe; Kazuhiko Koike
Journal:  Invest New Drugs       Date:  2016-06-23       Impact factor: 3.850

Review 5.  The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling.

Authors:  Barbara Bottazzi; Antonio Inforzato; Massimo Messa; Marialuisa Barbagallo; Elena Magrini; Cecilia Garlanda; Alberto Mantovani
Journal:  J Hepatol       Date:  2016-02-26       Impact factor: 25.083

6.  Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma.

Authors:  Hyoung Woo Kim; Jong-Chan Lee; Kyu-Hyun Paik; Yoon Suk Lee; Jin-Hyeok Hwang; Jaihwan Kim
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

7.  Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.

Authors:  S Kondo; H Ueno; H Hosoi; J Hashimoto; C Morizane; F Koizumi; K Tamura; T Okusaka
Journal:  Br J Cancer       Date:  2013-07-04       Impact factor: 7.640

Review 8.  Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis.

Authors:  Yixiang Mao; Min Tao; Xiaoyan Jia; Hong Xu; Kai Chen; Hongwei Tang; Donghui Li
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

9.  Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.

Authors:  S Mitsunaga; M Ikeda; S Shimizu; I Ohno; J Furuse; M Inagaki; S Higashi; H Kato; K Terao; A Ochiai
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

Review 10.  Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.

Authors:  Shiro Kimbara; Shunsuke Kondo
Journal:  World J Gastroenterol       Date:  2016-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.